Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (4999)	8/10/2001 3:09:54 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Mark, <<provisions for renegotiation or SEPR concurrence>> in a SGP munch. I very much doubt there are any given this wasn't a co-promote type deal but a straight license. Also unlikely to be any antitrust issues given that SGP already has Claritin, which will remain a major brand even after it goes generic. There may just be too much uncertainty surrounding SGP for a munch to happen now. I agree that we likely won't see Clarinex on the market this year. Peter